137 related articles for article (PubMed ID: 34938290)
1. Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19.
Tran TNM; May BP; Ung TT; Nguyen MK; Nguyen TTT; Dinh VL; Doan CC; Tran TV; Khong H; Nguyen TTT; Hua HQH; Nguyen VA; Ha TP; Phan DL; Nguyen TA; Bui TN; Tu TM; Nguyen TT; Le TTH; Dong TL; Huynh TH; Ho PH; Le NTT; Truong CT; Pham HP; Luong CY; Y NL; Cao MN; Nguyen DK; Le TT; Vuong DC; Nguyen LKH; Do MS
Front Immunol; 2021; 12():766112. PubMed ID: 34938290
[TBL] [Abstract][Full Text] [Related]
2. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.
Lu M; Dravid P; Zhang Y; Trivedi S; Li A; Harder O; Kc M; Chaiwatpongsakorn S; Zani A; Kenney A; Zeng C; Cai C; Ye C; Liang X; Shimamura M; Liu SL; Mejias A; Ramilo O; Boyaka PN; Qiu J; Martinez-Sobrido L; Yount JS; Peeples ME; Kapoor A; Niewiesk S; Li J
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688034
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.
Tcheou J; Raskin A; Singh G; Kawabata H; Bielak D; Sun W; González-Domínguez I; Sather DN; García-Sastre A; Palese P; Krammer F; Carreño JM
Front Immunol; 2021; 12():791764. PubMed ID: 34868082
[TBL] [Abstract][Full Text] [Related]
5. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
Front Immunol; 2021; 12():697074. PubMed ID: 34262569
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
[TBL] [Abstract][Full Text] [Related]
9. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
10. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
11. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.
Martinez DR; Schäfer A; Leist SR; De la Cruz G; West A; Atochina-Vasserman EN; Lindesmith LC; Pardi N; Parks R; Barr M; Li D; Yount B; Saunders KO; Weissman D; Haynes BF; Montgomery SA; Baric RS
Science; 2021 Aug; 373(6558):991-998. PubMed ID: 34214046
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
Shanmugaraj B; Khorattanakulchai N; Panapitakkul C; Malla A; Im-Erbsin R; Inthawong M; Sunyakumthorn P; Hunsawong T; Klungthong C; Reed MC; Kemthong T; Suttisan N; Malaivijitnond S; Srimangkornkaew P; Klinkhamhom A; Manopwisedjaroen S; Thitithanyanont A; Taychakhoonavudh S; Phoolcharoen W
Vaccine; 2022 Jul; 40(32):4440-4452. PubMed ID: 35697573
[TBL] [Abstract][Full Text] [Related]
13. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.
Conforti A; Marra E; Palombo F; Roscilli G; Ravà M; Fumagalli V; Muzi A; Maffei M; Luberto L; Lione L; Salvatori E; Compagnone M; Pinto E; Pavoni E; Bucci F; Vitagliano G; Stoppoloni D; Pacello ML; Cappelletti M; Ferrara FF; D'Acunto E; Chiarini V; Arriga R; Nyska A; Di Lucia P; Marotta D; Bono E; Giustini L; Sala E; Perucchini C; Paterson J; Ryan KA; Challis AR; Matusali G; Colavita F; Caselli G; Criscuolo E; Clementi N; Mancini N; Groß R; Seidel A; Wettstein L; Münch J; Donnici L; Conti M; De Francesco R; Kuka M; Ciliberto G; Castilletti C; Capobianchi MR; Ippolito G; Guidotti LG; Rovati L; Iannacone M; Aurisicchio L
Mol Ther; 2022 Jan; 30(1):311-326. PubMed ID: 34547465
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.
Capone S; Raggioli A; Gentile M; Battella S; Lahm A; Sommella A; Contino AM; Urbanowicz RA; Scala R; Barra F; Leuzzi A; Lilli E; Miselli G; Noto A; Ferraiuolo M; Talotta F; Tsoleridis T; Castilletti C; Matusali G; Colavita F; Lapa D; Meschi S; Capobianchi M; Soriani M; Folgori A; Ball JK; Colloca S; Vitelli A
Mol Ther; 2021 Aug; 29(8):2412-2423. PubMed ID: 33895322
[TBL] [Abstract][Full Text] [Related]
15. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
Sun S; He L; Zhao Z; Gu H; Fang X; Wang T; Yang X; Chen S; Deng Y; Li J; Zhao J; Li L; Li X; He P; Li G; Li H; Zhao Y; Gao C; Lang X; Wang X; Fei G; Li Y; Geng S; Gao Y; Wei W; Hu Z; Han G; Sun Y
Cell Mol Immunol; 2021 Apr; 18(4):1070-1073. PubMed ID: 33731916
[No Abstract] [Full Text] [Related]
16. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.
DiPiazza AT; Leist SR; Abiona OM; Moliva JI; Werner A; Minai M; Nagata BM; Bock KW; Phung E; Schäfer A; Dinnon KH; Chang LA; Loomis RJ; Boyoglu-Barnum S; Alvarado GS; Sullivan NJ; Edwards DK; Morabito KM; Mascola JR; Carfi A; Corbett KS; Moore IN; Baric RS; Graham BS; Ruckwardt TJ
Immunity; 2021 Aug; 54(8):1869-1882.e6. PubMed ID: 34270939
[TBL] [Abstract][Full Text] [Related]
18. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
[TBL] [Abstract][Full Text] [Related]
19. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.
Liu J; Budylowski P; Samson R; Griffin BD; Babuadze G; Rathod B; Colwill K; Abioye JA; Schwartz JA; Law R; Yip L; Ahn SK; Chau S; Naghibosadat M; Arita Y; Hu Q; Yue FY; Banerjee A; Hardy WR; Mossman K; Mubareka S; Kozak RA; Pollanen MS; Martin Orozco N; Gingras AC; Marcusson EG; Ostrowski MA
Sci Adv; 2022 Jan; 8(3):eabj9815. PubMed ID: 35044832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
